← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
olmutinib
L01EB06
Forms & Strengths
- Oral tablets: 200 mg
- Oral tablets: 400 mg
Adult Dosing
- Non-small cell lung cancer (NSCLC): 800 mg orally once daily until disease progression or unacceptable toxicity
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of adult patients with T790M mutation-positive epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) who have progressed on or after EGFR tyrosine kinase inhibitor therapy
Mechanism of Action
- Irreversible tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of EGFR, including the T790M resistance mutation, leading to inhibition of downstream signaling and tumor cell apoptosis
Contraindications
- Known hypersensitivity to olmutinib or any of its excipients
Adverse Reactions
- Diarrhea
- Nausea
- Rash
- Pruritus
- Decreased appetite
- Fatigue
- Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome
- Interstitial lung disease (ILD)
Drug Interactions
- Strong CYP3A4 inducers may decrease olmutinib plasma concentrations and efficacy
- Strong CYP3A4 inhibitors may increase olmutinib plasma concentrations and toxicity risk
- Gastric acid-reducing agents may alter absorption profiles
Curated Content: Needs Vetting Before Put to Clinical Use